Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.

Interactome maps are valuable resources to elucidate protein function and disease mechanisms. Here, we report on an interactome map that focuses on neurodegenerative disease (ND), connects ∼5,000 human proteins via ∼30,000 candidate interactions and is generated by systematic yeast two-hybrid interaction screening of ∼500 ND-related proteins and integration of literature interactions. This network reveals interconnectivity across diseases and links many known ND-causing proteins, such as α-synuclein, TDP-43, and ATXN1, to a host of proteins previously unrelated to NDs. It facilitates the identification of interacting proteins that significantly influence mutant TDP-43 and HTT toxicity in transgenic flies, as well as of ARF-GEP100 that controls misfolding and aggregation of multiple ND-causing proteins in experimental model systems. Furthermore, it enables the prediction of ND-specific subnetworks and the identification of proteins, such as ATXN1 and MKL1, that are abnormally aggregated in postmortem brains of Alzheimer's disease patients, suggesting widespread protein aggregation in NDs.

ANAT 2.0: reconstructing functional protein subnetworks.

BACKGROUND: ANAT is a graphical, Cytoscape-based tool for the inference of protein networks that underlie a process of interest. The ANAT tool allows the user to perform network reconstruction under several scenarios in a number of organisms including yeast and human. RESULTS: Here we report on a new version of the tool, ANAT 2.0, which introduces substantial code and database updates as well as several new network reconstruction algorithms that greatly extend the applicability of the tool to biological data sets. CONCLUSIONS: ANAT 2.0 is an up-to-date network reconstruction tool that addresses several reconstruction challenges across multiple species.

Metabolic Network Prediction of Drug Side Effects.

Drug side effects levy a massive cost on society through drug failures, morbidity, and mortality cases every year, and their early detection is critically important. Here, we describe the array of model-based phenotype predictors (AMPP), an approach that leverages medical informatics resources and a human genome-scale metabolic model (GSMM) to predict drug side effects. AMPP is substantially predictive (AUC > 0.7) for >70 drug side effects, including very serious ones such as interstitial nephritis and extrapyramidal disorders. We evaluate AMPP's predictive signal through cross-validation, comparison across multiple versions of a side effects database, and co-occurrence analysis of drug side effect associations in scientific abstracts (hypergeometric p value = 2.2e-40). AMPP outperforms a previous biochemical structure-based method in predicting metabolically based side effects (aggregate AUC = 0.65 versus 0.59). Importantly, AMPP enables the identification of key metabolic reactions and biomarkers that are predictive of specific side effects. Taken together, this work lays a foundation for future detection of metabolically grounded side effects during early stages of drug development.

A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1.

Splicing aberrations are prominent drivers of cancer, yet the regulatory pathways controlling them are mostly unknown. Here we develop a method that integrates physical interaction, gene expression, and alternative splicing data to construct the largest map of transcriptomic and proteomic interactions leading to cancerous splicing aberrations defined to date, and identify driver pathways therein. We apply our method to colon adenocarcinoma and non-small-cell lung carcinoma. By focusing on colon cancer, we reveal a novel tumor-favoring regulatory pathway involving the induction of the transcription factor MYC by the transcription factor ELK1, as well as the subsequent induction of the alternative splicing factor PTBP1 by both. We show that PTBP1 promotes specific RAC1,NUMB, and PKM splicing isoforms that are major triggers of colon tumorigenesis. By testing the pathway's activity in patient tumor samples, we find ELK1,MYC, and PTBP1 to be overexpressed in conjunction with oncogenic KRAS mutations, and show that these mutations increase ELK1 levels via the RAS-MAPK pathway. We thus illuminate, for the first time, a full regulatory pathway connecting prevalent cancerous mutations to functional tumor-inducing splicing aberrations. Our results demonstrate our method is applicable to different cancers to reveal regulatory pathways promoting splicing aberrations.

Systematic identification and correction of annotation errors in the genetic interaction map of Saccharomyces cerevisiae.

The yeast mutant collections are a fundamental tool in deciphering genomic organization and function. Over the last decade, they have been used for the systematic exploration of ∼6 000 000 double gene mutants, identifying and cataloging genetic interactions among them. Here we studied the extent to which these data are prone to neighboring gene effects (NGEs), a phenomenon by which the deletion of a gene affects the expression of adjacent genes along the genome. Analyzing ∼90,000 negative genetic interactions observed to date, we found that more than 10% of them are incorrectly annotated due to NGEs. We developed a novel algorithm, GINGER, to identify and correct erroneous interaction annotations. We validated the algorithm using a comparative analysis of interactions from Schizosaccharomyces pombe. We further showed that our predictions are significantly more concordant with diverse biological data compared to their mis-annotated counterparts. Our work uncovered about 9500 new genetic interactions in yeast.

Regulation of Sec16 levels and dynamics links proliferation and secretion.

We currently lack a broader mechanistic understanding of the integration of the early secretory pathway with other homeostatic processes such as cell growth. Here, we explore the possibility that Sec16A, a major constituent of endoplasmic reticulum exit sites (ERES), acts as an integrator of growth factor signaling. Surprisingly, we find that Sec16A is a short-lived protein that is regulated by growth factors in a manner dependent on Egr family transcription factors. We hypothesize that Sec16A acts as a central node in a coherent feed-forward loop that detects persistent growth factor stimuli to increase ERES number. Consistent with this notion, Sec16A is also regulated by short-term growth factor treatment that leads to increased turnover of Sec16A at ERES. Finally, we demonstrate that Sec16A depletion reduces proliferation, whereas its overexpression increases proliferation. Together with our finding that growth factors regulate Sec16A levels and its dynamics on ERES, we propose that this protein acts as an integrator linking growth factor signaling and secretion. This provides a mechanistic basis for the previously proposed link between secretion and proliferation.

Experimental design schemes for learning Boolean network models.

MOTIVATION: A holy grail of biological research is a working model of the cell. Current modeling frameworks, especially in the protein-protein interaction domain, are mostly topological in nature, calling for stronger and more expressive network models. One promising alternative is logic-based or Boolean network modeling, which was successfully applied to model signaling regulatory circuits in human. Learning such models requires observing the system under a sufficient number of different conditions. To date, the amount of measured data is the main bottleneck in learning informative Boolean models, underscoring the need for efficient experimental design strategies. RESULTS: We developed novel design approaches that greedily select an experiment to be performed so as to maximize the difference or the entropy in the results it induces with respect to current best-fit models. Unique to our maximum difference approach is the ability to account for all (possibly exponential number of) Boolean models displaying high fit to the available data. We applied both approaches to simulated and real data from the EFGR and IL1 signaling systems in human. We demonstrate the utility of the developed strategies in substantially improving on a random selection approach. Our design schemes highlight the redundancy in these datasets, leading up to 11-fold savings in the number of experiments to be performed. AVAILABILITY AND IMPLEMENTATION: Source code will be made available upon acceptance of the manuscript.

Pathway-based analysis of genomic variation data.

A holy grail of genetics is to decipher the mapping from genotype to phenotype. Recent advances in sequencing technologies allow the efficient genotyping of thousands of individuals carrying a particular phenotype in an effort to reveal its genetic determinants. However, the interpretation of these data entails tackling significant statistical and computational problems that stem from the complexity of human phenotypes and the huge genotypic search space. Recently, an alternative pathway-level analysis has been employed to combat these problems. In this review we discuss these developments, describe the challenges involved and outline possible solutions and future directions for improvement.

Alternative splicing regulates biogenesis of miRNAs located across exon-intron junctions.

The initial step in microRNA (miRNA) biogenesis requires processing of the precursor miRNA (pre-miRNA) from a longer primary transcript. Many pre-miRNAs originate from introns, and both a mature miRNA and a spliced RNA can be generated from the same transcription unit. We have identified a mechanism in which RNA splicing negatively regulates the processing of pre-miRNAs that overlap exon-intron junctions. Computational analysis identified dozens of such pre-miRNAs, and experimental validation demonstrated competitive interaction between the Microprocessor complex and the splicing machinery. Tissue-specific alternative splicing regulates maturation of one such miRNA, miR-412, resulting in effects on its targets that code a protein network involved in neuronal cell death processes. This mode of regulation specifically controls maturation of splice-site-overlapping pre-miRNAs but not pre-miRNAs located completely within introns or exons of the same transcript. Our data present a biological role of alternative splicing in regulation of miRNA biogenesis.

A genetic screen for high copy number suppressors of the synthetic lethality between elg1Δ and srs2Δ in yeast.

Elg1 and Srs2 are two proteins involved in maintaining genome stability in yeast. After DNA damage, the homotrimeric clamp PCNA, which provides stability and processivity to DNA polymerases and serves as a docking platform for DNA repair enzymes, undergoes modification by the ubiquitin-like molecule SUMO. PCNA SUMOylation helps recruit Srs2 and Elg1 to the replication fork. In the absence of Elg1, both SUMOylated PCNA and Srs2 accumulate at the chromatin fraction, indicating that Elg1 is required for removing SUMOylated PCNA and Srs2 from DNA. Despite this interaction, which suggests that the two proteins work together, double mutants elg1Δ srs2Δ have severely impaired growth as haploids and exhibit synergistic sensitivity to DNA damage and a synergistic increase in gene conversion. In addition, diploid elg1Δ srs2Δ double mutants are dead, which implies that an essential function in the cell requires at least one of the two gene products for survival. To gain information about this essential function, we have carried out a high copy number suppressor screen to search for genes that, when overexpressed, suppress the synthetic lethality between elg1Δ and srs2Δ. We report the identification of 36 such genes, which are enriched for functions related to DNA- and chromatin-binding, chromatin packaging and modification, and mRNA export from the nucleus.

iPoint: an integer programming based algorithm for inferring protein subnetworks.

Large scale screening experiments have become the workhorse of molecular biology, producing data at an ever increasing scale. The interpretation of such data, particularly in the context of a protein interaction network, has the potential to shed light on the molecular pathways underlying the phenotype or the process in question. A host of approaches have been developed in recent years to tackle this reconstruction challenge. These approaches aim to infer a compact subnetwork that connects the genes revealed by the screen while optimizing local (individual path lengths) or global (likelihood) aspects of the subnetwork. Yosef et al. [Mol. Syst. Biol., 2009, 5, 248] were the first to provide a joint optimization of both criteria, albeit approximate in nature. Here we devise an integer linear programming formulation for the joint optimization problem, allowing us to solve it to optimality in minutes on current networks. We apply our algorithm, iPoint, to various data sets in yeast and human and evaluate its performance against state-of-the-art algorithms. We show that iPoint attains very compact and accurate solutions that outperform previous network inference algorithms with respect to their local and global attributes, their consistency across multiple experiments targeting the same pathway, and their agreement with current biological knowledge.

ANAT: a tool for constructing and analyzing functional protein networks.

Genome-scale screening studies are gradually accumulating a wealth of data on the putative involvement of hundreds of genes in various cellular responses or functions. A fundamental challenge is to chart the molecular pathways that underlie these systems. ANAT is an interactive software tool, implemented as a Cytoscape plug-in, for elucidating functional networks of proteins. It encompasses a number of network inference algorithms and provides access to networks of physical associations in several organisms. In contrast to existing software tools, ANAT can be used to infer subnetworks that connect hundreds of proteins to each other or to a given set of "anchor" proteins, a fundamental step in reconstructing cellular subnetworks. The interactive component of ANAT provides an array of tools for evaluating and exploring the resulting subnetwork models and for iteratively refining them. We demonstrate the utility of ANAT by studying the crosstalk between the autophagic and apoptotic cell death modules in humans, using a network of physical interactions. Relative to published software tools, ANAT is more accurate and provides more features for comprehensive network analysis. The latest version of the software is available at http://www.cs.tau.ac.il/~bnet/ANAT_SI.

An algorithmic framework for predicting side effects of drugs.

One of the critical stages in drug development is the identification of potential side effects for promising drug leads. Large-scale clinical experiments aimed at discovering such side effects are very costly and may miss subtle or rare side effects. Previous attempts to systematically predict side effects are sparse and consider each side effect independently. In this work, we report on a novel approach to predict the side effects of a given drug, taking into consideration information on other drugs and their side effects. Starting from a query drug, a combination of canonical correlation analysis and network-based diffusion is applied to predict its side effects. We evaluate our method by measuring its performance in a cross validation setting using a comprehensive data set of 692 drugs and their known side effects derived from package inserts. For 34% of the drugs, the top scoring side effect matches a known side effect of the drug. Remarkably, even on unseen data, our method is able to infer side effects that highly match existing knowledge. In addition, we show that our method outperforms a prediction scheme that considers each side effect separately. Our method thus represents a promising step toward shortcutting the process and reducing the cost of side effect elucidation.

Combining drug and gene similarity measures for drug-target elucidation.

Understanding drugs and their modes of action is a fundamental challenge in systems medicine. Key to addressing this challenge is the elucidation of drug targets, an important step in the search for new drugs or novel targets for existing drugs. Incorporating multiple biological information sources is of essence for improving the accuracy of drug target prediction. In this article, we introduce a novel framework--Similarity-based Inference of drug-TARgets (SITAR)--for incorporating multiple drug-drug and gene-gene similarity measures for drug target prediction. The framework consists of a new scoring scheme for drug-gene associations based on a given pair of drug-drug and gene-gene similarity measures, combined with a logistic regression component that integrates the scores of multiple measures to yield the final association score. We apply our framework to predict targets for hundreds of drugs using both commonly used and novel drug-drug and gene-gene similarity measures and compare our results to existing state of the art methods, markedly outperforming them. We then employ our framework to make novel target predictions for hundreds of drugs; we validate these predictions via curated databases that were not used in the learning stage. Our framework provides an extensible platform for incorporating additional emerging similarity measures among drugs and genes. Supplementary Material is available at www.liebertonline.com/cmb.